MARY DORE: Open Payments
NPI 1689438764 · SULPHUR, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$559 in 28 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $559
Food & beverage: $559
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $163 |
| Vanda Pharmaceuticals Inc. | 3 | $73 |
| Sumitomo Pharma America, Inc. | 3 | $72 |
| Axsome Therapeutics, Inc. | 3 | $57 |
| ABBVIE INC. | 2 | $49 |
| Evofem Biosciences, Inc. | 3 | $29 |
| TOLMAR, INC. | 1 | $21 |
| Lundbeck LLC | 1 | $19 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $15 |
Products named: CAPLYTA, FANAPT, GEMTESA, Auvelity, VRAYLAR, Phexxi, JATENZO, REXULTI.
Industry payments across LA — which companies pay providers there.
